Get started
NATCO Pharma LimitedNATCO Pharma LimitedNATCO Pharma Limited

NATCO Pharma Limited

No trades
OverviewFinancialsNewsCommunityTechnicalsForecastsSeasonalsETFs
Full chart
Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪210.08 B‬ INR
Dividend yield (indicated)
0.43%
Price to earnings Ratio (TTM)
13.50
Basic EPS (TTM)
86.95 INR
Net income (FY)
‪18.85 B‬ INR
Revenue (FY)
‪44.15 B‬ INR
Shares float
‪87.23 M‬
Beta (1Y)
0.57

Employees


Employees (FY)
‪4.96 K‬
Change (1Y)
+155 +3.23%
Revenue / Employee (1Y)
‪8.91 M‬ INR
Net income / Employee (1Y)
‪3.81 M‬ INR

About NATCO Pharma Limited


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Rajeev Nannapaneni
Website
natcopharma.co.in
Headquarters
Hyderabad
Founded
1981
IPO date
Jan 23, 1995
Identifiers
2
ISIN INE987B01026
CFI code
ESVUFN
NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. It operates through the following segments: Domestic Formulations, International Formulations, and Active Pharmaceutical Ingredients. The Domestic Formulations segment operates in the divisions of oncology, pharma specialties and CnD. The International Formulations segment exports its FDF products from India to several international geographies either through its local partners or directly through its subsidiaries such as in Canada and Brazil. The Active Pharmaceutical Ingredients segment is strategically important as it develops APIs for the captive consumption of many of NATCO's critical FDF products in addition to supplying to direct customers. The company was founded by Venkaiah Chowdary Nannapaneni in 1981 and is headquartered in Hyderabad, India.

Check out other big names from the same industry as NATCOPHARM.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


AVEM
Avantis Emerging Markets Equity ETF
Weight 0.02%
Market value ‪5.67 M‬
DFEM
Dimensional Emerging Markets Core Equity 2 ETF
Weight 0.02%
Market value ‪1.90 M‬
SMIN
Ishares MSCI India Small Cap ETF
Weight 0.29%
Market value ‪1.79 M‬
EPI
WisdomTree India Earnings Fund
Weight 0.09%
Market value ‪1.52 M‬
HDFCSML250
HDFC Nifty Smallcap 250 ETF
Weight 0.49%
Market value ‪1.33 M‬
DGS
WisdomTree Emerging Market SmallCap Fund
Weight 0.06%
Market value ‪1.08 M‬
SMALLCAP
Mirae Asset Nifty Smallcap 250 Momentum Quality 100 ETF Units Exchange Traded Fund
Weight 0.92%
Market value ‪913.29 K‬
DFEV
Dimensional Emerging Markets Value ETF
Weight 0.02%
Market value ‪433.88 K‬
EEMS
iShares MSCI Emerging Markets Small Cap ETF
Weight 0.06%
Market value ‪271.81 K‬
SPYX
SSgA SPDR ETFs Europe I Plc - MSCI Em. Mkts. Small Cap ETF
Weight 0.05%
Market value ‪266.99 K‬
EWX
State Street SPDR S&P Emerging Markets Small Cap ETF
Weight 0.03%
Market value ‪226.62 K‬

Explore more ETFs 

Frequently asked questions


The current price of NATCOPHARM is 1,203.85 INR — it has increased by 2.65% in the past 24 hours. Watch NATCO Pharma Limited stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BSE exchange NATCO Pharma Limited stocks are traded under the ticker NATCOPHARM.
NATCOPHARM stock has risen by 4.48% compared to the previous week, the month change is a 9.72% rise, over the last year NATCO Pharma Limited has showed a 45.45% increase.
We've gathered analysts' opinions on NATCO Pharma Limited future price: according to them, NATCOPHARM price has a max estimate of 1,180.00 INR and a min estimate of 712.00 INR. Watch NATCOPHARM chart and read a more detailed NATCO Pharma Limited stock forecast: see what analysts think of NATCO Pharma Limited and suggest that you do with its stocks.
NATCOPHARM reached its all-time high on Sep 12, 2024 with the price of 1,638.35 INR, and its all-time low was 7.60 INR and was reached on Oct 27, 2008. View more price dynamics on NATCOPHARM chart.
See other stocks reaching their highest and lowest prices.
NATCOPHARM stock is 2.14% volatile and has beta coefficient of 0.57. Track NATCO Pharma Limited stock price on the chart and check out the list of the most volatile stocks — is NATCO Pharma Limited there?
Today NATCO Pharma Limited has the market capitalization of ‪210.08 B‬, it has increased by 2.12% over the last week.
Yes, you can track NATCO Pharma Limited financials in yearly and quarterly reports right on TradingView.
NATCO Pharma Limited is going to release the next earnings report on Jun 1, 2026. Keep track of upcoming events with our Earnings Calendar.
NATCOPHARM earnings for the last quarter are 8.43 INR per share, whereas the estimation was 5.27 INR resulting in a 60.06% surprise. The estimated earnings for the next quarter are 15.76 INR per share. See more details about NATCO Pharma Limited earnings.
NATCO Pharma Limited revenue for the last quarter amounts to ‪6.47 B‬ INR, despite the estimated figure of ‪6.90 B‬ INR. In the next quarter, revenue is expected to reach ‪7.60 B‬ INR.
NATCOPHARM net income for the last quarter is ‪1.51 B‬ INR, while the quarter before that showed ‪5.18 B‬ INR of net income which accounts for 0.00% change. Track more NATCO Pharma Limited financial stats to get the full picture.
NATCO Pharma Limited dividend yield was 0.75% in 2024, and payout ratio reached 5.70%. The year before the numbers were 1.00% and 12.28% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of May 15, 2026, the company has ‪4.96 K‬ employees. See our rating of the largest employees — is NATCO Pharma Limited on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NATCO Pharma Limited EBITDA is ‪18.57 B‬ INR, and current EBITDA margin is 50.90%. See more stats in NATCO Pharma Limited financial statements.
Like other stocks, NATCOPHARM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NATCO Pharma Limited stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NATCO Pharma Limited technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NATCO Pharma Limited stock shows the strong buy signal. See more of NATCO Pharma Limited technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.